Kisqali 200 mg for certain type of breast cancer

Kisqali 200 mg (Ribociclib) is a prescription medicine used to treat advanced or metastatic breast cancer in women who are hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2–).

It belongs to a class of drugs known as CDK4/6 inhibitors, which work by blocking specific enzymes that promote cancer cell division and growth.
Kisqali helps slow down or stop cancer progression when used together with hormonal therapy such as Letrozole or Fulvestrant.

The medicine comes in 200 mg film-coated tablets and is taken orally under medical supervision.

Indications of Use

• Treatment of HR+ / HER2– advanced or metastatic breast cancer in postmenopausal women or premenopausal women (when combined with hormonal therapy).

• Used in combination with an aromatase inhibitor or Fulvestrant.

• To be prescribed and monitored by an oncologist only.

Warnings & Precautions

• Do not use during pregnancy or breastfeeding. Effective contraception must be used during and after treatment as advised by your doctor.

• Regular monitoring of liver function, blood counts, and heart rhythm (ECG) is required.

• Use with caution if you have:

  • Heart rhythm disorders (e.g., QT prolongation)

  • Liver or kidney impairment

• Possible side effects include fatigue, nausea, diarrhea, decreased appetite, or temporary hair thinning.

• Inform your doctor of all medicines and supplements you are taking to avoid drug interactions, especially with antibiotics, antifungal drugs, and heart medications.

• Do not stop or adjust the dose without consulting your doctor, even if you feel better.

• Store at room temperature, away from heat, moisture, and out of reach of children.